Brought to you by 
Vertex and Genomics PLC ink collaboration for precision medicines
20 Nov 2018
Executive Summary
Vertex Pharmaceuticals Inc. and Genomics PLC agreed to collaborate in a three-year deal (possible extension to five) in which the latter will use its machine learning platform to assist Vertex in its discovery of selected targets for precision medicine.
Deal Industry
- Digital Health
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vertex and Genomics PLC ink collaboration for precision medicines
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice